RecruitingNCT07029581
ACP-204 for psychosis in Lewy body dementia
About this title
Read the official source — NCT07029581Medication studyAges 55–84Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 55 years to 84 years.
- Listed locations
- Irvine and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 6, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 180
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 55 Years to 84 Years
- Official registry ID
- NCT07029581
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Irvine, United States · Aurora, United States · Washington D.C., United States
47 more locations
- Aventura, United States
- Boca Raton, United States
- Clermont, United States
- Gainesville, United States
- Hialeah, United States
- Lady Lake, United States
- Maitland, United States
- Miami, United States
- West Palm Beach, United States
- Honolulu, United States
- Chicago, United States
- Kansas City, United States
- Commack, United States
- Chapel Hill, United States
- Cleveland, United States
- Columbus, United States
- Tulsa, United States
- Abington, United States
- Cypress, United States
- Houston, United States
- San Antonio, United States
- Stafford, United States
- Richmond, United States
- Kirkland, United States
- Cherven Bryag, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Brno, Czechia
- Choceň, Czechia
- Prague, Czechia
- Rychnov nad Kněžnou, Czechia
- Toulouse, France
- Lille, France
- Paris, France
- Villeurbanne, France
- Bron, France
- Strasbourg, France
- Tours, France
- Vandœuvre-lès-Nancy, France
- Naples, Italy
- Salerno, Italy
- Brescia, Italy
- Roma, Italy
- Belgrade, Serbia
- Kragujevac, Serbia
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including ACP-204 and Placebo.
Who can participate?
Listed age limits: 55 years to 84 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....